Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma Who Have Had Prior Radiation Therapy
OBJECTIVES: I. Determine the toxicity and response to intensive chemotherapy followed by
autologous peripheral blood stem cell transplantation in patients with Hodgkin's disease or
non-Hodgkin's lymphoma who have received prior chemotherapy and/or radiotherapy.
OUTLINE: Patients receive oral busulfan every 6 hours on days -9 to -6 and cyclophosphamide
IV over 2 hours on days -5 to -2. Autologous peripheral blood stem cells are reinfused on
day 0. Patients are followed monthly for 1 year.
PROJECTED ACCRUAL: Not specified
Primary Purpose: Treatment
Leo I. Gordon, MD
Robert H. Lurie Cancer Center
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|